DE1963496A1 - Stomach and intestinal disorders treatment - compsn - Google Patents
Stomach and intestinal disorders treatment - compsnInfo
- Publication number
- DE1963496A1 DE1963496A1 DE19691963496 DE1963496A DE1963496A1 DE 1963496 A1 DE1963496 A1 DE 1963496A1 DE 19691963496 DE19691963496 DE 19691963496 DE 1963496 A DE1963496 A DE 1963496A DE 1963496 A1 DE1963496 A1 DE 1963496A1
- Authority
- DE
- Germany
- Prior art keywords
- dichloro
- quinaldine
- methoxyethoxy
- diphenyl
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims description 7
- 208000028774 intestinal disease Diseases 0.000 title claims description 5
- 210000002784 stomach Anatomy 0.000 title claims description 5
- 208000018556 stomach disease Diseases 0.000 title claims description 5
- 239000001814 pectin Substances 0.000 claims abstract description 14
- 235000010987 pectin Nutrition 0.000 claims abstract description 14
- 229920001277 pectin Polymers 0.000 claims abstract description 14
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229920002253 Tannate Polymers 0.000 claims abstract description 5
- CIKWKGFPFXJVGW-UHFFFAOYSA-N ethacridine Chemical compound C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 CIKWKGFPFXJVGW-UHFFFAOYSA-N 0.000 claims abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 8
- 125000005853 β-dimethylaminoethyl group Chemical group 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- RXPAJWPEYBDXOG-UHFFFAOYSA-N hydron;methyl 4-methoxypyridine-2-carboxylate;chloride Chemical compound Cl.COC(=O)C1=CC(OC)=CC=N1 RXPAJWPEYBDXOG-UHFFFAOYSA-N 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000341 volatile oil Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 claims description 2
- 239000010643 fennel seed oil Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims 2
- 235000001050 hortel pimenta Nutrition 0.000 claims 2
- 150000005846 sugar alcohols Chemical class 0.000 claims 2
- 244000090896 Nigella sativa Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 235000008541 fennel flower Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- -1 alpha, alpha-diphenyl-alpha-(beta-methoxyethoxy)acetic acid beta-dimethylaminoethyl ester orotic acid salt Chemical class 0.000 abstract description 3
- QGWDKKHSDXWPET-UHFFFAOYSA-E pentabismuth;oxygen(2-);nonahydroxide;tetranitrate Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O-2].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O QGWDKKHSDXWPET-UHFFFAOYSA-E 0.000 abstract description 2
- 239000004411 aluminium Substances 0.000 abstract 1
- GPTXWRGISTZRIO-UHFFFAOYSA-N chlorquinaldol Chemical compound ClC1=CC(Cl)=C(O)C2=NC(C)=CC=C21 GPTXWRGISTZRIO-UHFFFAOYSA-N 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 235000019477 peppermint oil Nutrition 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- JFVXEJADITYJHK-UHFFFAOYSA-L disodium 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [Na+].[Na+].Oc1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=Nc2ccc(cc2C1=O)S([O-])(=O)=O JFVXEJADITYJHK-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940031625 pectin 300 mg Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/235—Foeniculum (fennel)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Pharmazeutisches Präparat zur Behandlung von Magen-Darm-Erkrankungen Die vorliegende Erfindung betrifft ein neues pharmazeutisches Präparat für die Behandlung und/oder Prophylaxe von akuten und chronischen Magen- und Darmerkrankungen, ganz besonders dysbiotischer und/oder infektiöser Art, also diarrhoischer Art, so akuter Diarrhoe, Sommerdiarrhoe, chronischer oder rezidivierender Diarrhoe, Enteritis, Enterocolitis und parasitärer Mischinfektionen, Amoebiasis, insbesondere ihrer chronischen Formen, wie Giardiasis, Urichomoniasis und intestinale Moniliasis.Pharmaceutical preparation for the treatment of gastrointestinal diseases The present invention relates to a new pharmaceutical preparation for treatment and / or prophylaxis of acute and chronic stomach and intestinal diseases, whole especially dysbiotic and / or infectious, i.e. diarrheal, so acute Diarrhea, summer diarrhea, chronic or recurrent diarrhea, enteritis, Enterocolitis and mixed parasitic infections, amoebiasis, especially their chronic ones Forms such as giardiasis, urichomoniasis and intestinal moniliasis.
Die vorliegende Erfindung erweist sich besonders nützlich für die Behandlung der Obstipation, des Meteorismus und der Flatulenz und allgemein bei Dysbiose der Keimbesiedlung des Darmes, ganz besonders aber für die Behandlung der schmerzhaften Formen aller dieser Krankheiten.The present invention proves particularly useful for Treatment of constipation, meteorism and flatulence and in general Dysbiosis of the colonization of germs in the intestine, but especially for the treatment of the painful forms of all of these diseases.
Es ist allgemein bekannt, wie auseinandergesetzt wurde, daß insbesondere die akuten Magen- und Darmerkrankungen plötzlich mit starken schmerzhaften Angriffen beginnen, so daß oft die Ursachen der heftigen Schmerzen im Bereich der Magen-Darmsphäre nicht sofort erkannt werden können, und daß die Art dieser Schmerzen als Zivilisationserscheinung im Wachsen begriffen ist. Eine Magen-Darm-Infektion stellt immer ein komplexes Geschehen vielfacher Formen und Angriffspunkte dar, so Infektion, Entzündung, Schmerzen, Durchfälle, Koliken, tibelkeft und Unwohlsein.It is well known how it was stated that in particular the acute stomach and intestinal diseases suddenly with severe painful attacks begin so that often the causes of severe pain in the gastrointestinal sphere cannot be recognized at once, and that the nature of this pain is a phenomenon of civilization is growing. A gastrointestinal infection is always a complex matter multiple forms and points of attack, such as infection, inflammation, pain, diarrhea, Colic, tibelkeft and malaise.
Die bisher angewandten Mittel haben stets nur eine Erscheinung angegangen, entweder die Infektion und die Durchfälle, oder die kolikartigen Schmerzen, so daß ein Erfolg bescheiden blieb und eine erfolgreiche Therapie sich über trage und Wochen hinziehen mußte.The means used up to now have only ever addressed one phenomenon, either the infection and the diarrhea, or the colicky pains, so that Success remained modest and successful therapy took days and weeks had to move.
Es wurde nun gefunden, daß die am Anfang genannten Erkrtnkungen rasch und schnell durch die vorliegende Erfindung behoben werden können. Die neue erfindtingsgemäße Subereitang setzt sich zusammen aus Nr. Substanz Menge 1. 2-Äthoxy-6,9-diaminoacridinlactat 10 - 30 mg 2. 5, 7-Dichlor-8-oxy-chinaldin 20 -100 mg 3. α,α-Dimethyl-α-(ß-methoxyäthoxy)-essigsäure-(ß-dimethylaminoäthyl)-ester als orotsaures Salz 5 - 20 mg 4. Wismutnitrat (basisch) 40 -100 mg 5. Aluminiumtannat (aluminium tannium) 20 - 50 mg 6. Apfelpectin 300 -900 mg Der Zubereitung können noch Gallensäuren in Mengen von 10 - 50 mg zugesetzt werden.It has now been found that the diseases mentioned at the beginning quickly and can be quickly remedied by the present invention. The new according to the invention Subereitang is made up of No. Substance Quantity 1. 2-Ethoxy-6,9-diaminoacridine lactate 10-30 mg 2. 5, 7-dichloro-8-oxy-quinaldine 20-100 mg 3. α, α-Dimethyl-α- (β-methoxyethoxy) -acetic acid (β-dimethylaminoethyl) ester as orotate 5 - 20 mg 4. bismuth nitrate (basic) 40-100 mg 5. aluminum tannate (aluminum tannium) 20 - 50 mg 6. Apple pectin 300-900 mg of the preparation can Bile acids in quantities of 10 - 50 mg are also added.
Es wurde gefunden, daB sich die Bestandteile der Zusammensetzung in der antiinfektiösen Wirkung einerseits in vitro potenzieren, insbesondere gegenüber Enterokokken, und daß Magen- und Darmbeschwerden der verschiedenen Art, wie vorhergehend aufgezählt, rasch und nachhaltig behoben oder zumindest gelindert werden. Dieses ist für die praktische Anwendung entscheidend. Die Entzündungsstoffe des Magen- und Darmkanals werden durch die Erfindung rasch gebunden und abgeführt.It has been found that the constituents of the composition are in potentiate the anti-infectious effect on the one hand in vitro, in particular against Enterococci, and that gastrointestinal complaints of various kinds, as before listed, quickly and sustainably remedied or at least alleviated. This is crucial for practical application. The inflammatory substances of the gastric and the intestinal canal are quickly bound and drained by the invention.
Die Gesamtwirkung ist überraschend und nicht vorherzusehen gewesen.The overall effect was surprising and unforeseeable.
Die neuen Präparate der vorliegenden Zusammensetzung erhält man nach konventionellen Methoden der Arzneimittelherstellung, wobei man noch Hilfsstoffe verwenden kann, die mit den Wirkstoffen nicht reagieren, wie z.B. Gelatine, Lactose, Stärke, Stearinsäure, Stearylalkohol, Talkum, pflanzliche Öle, Benzylalkohole, Gummi, Propylenglykole, Polyalkyle oder andere Arzneimittelträger, Man kann auch Farb- oder Riechstoffe, vor allem ätherische Öle, wie Pfefferminzöle und Fenchelöle, zusetzen.The new preparations of the present composition are obtained after conventional methods of drug production, using auxiliary materials that do not react with the active ingredients, such as gelatin, lactose, Starch, stearic acid, stearyl alcohol, talc, vegetable oils, benzyl alcohol, rubber, Propylene glycols, polyalkyls or other excipients, one can also use colored or add fragrances, especially essential oils such as peppermint oils and fennel oils.
Das unter 3 genannte orotsaure Salz des Benzilesters kann auch durch Zusammenschmelzen mit einem Wachs, z.B.The orotic acid salt of the benzil ester mentioned under 3 can also be carried out by Fusing together with a wax, e.g.
Carnaubawachs oder Schellack, in eine protrahiert wirksame Form gebracht werden. Aber auch die gesamte Präparierung kann nach konventionellen Methoden gleichzeitig in eine sogenannte Retardform und/oder die schnellwirkende Form gebracht werden. In einfacher Weise lassen sich die Bestandteile einfach zusasmenpressen. Durch den Pectingehalt ist die Tablette haltbar und kann dragiert werden.Carnauba wax or shellac, brought into a protracted effective form will. But the entire preparation can also be carried out simultaneously using conventional methods be brought into a so-called sustained release form and / or the fast-acting form. The components can be simply pressed together in a simple manner. Through the The pectin content of the tablet is durable and can be coated with sugar-coated tablets.
Die neuen Präparate können sowohl in Kapseln, Tabletten, Dragees, Pulvern, Granulaten als auch in flüssigerForm, z.B. als Sirup, verwendet werden. Sie sind nicht nur in der Humanmedizin, sondern auch in der Veterinärmedizin für die Behandlung ähnlicher Krankheiten wertvoll, wie z.B.The new preparations are available in capsules, tablets, coated tablets, Powders, granules and also in liquid form, e.g. as syrup, can be used. They are not only used in human medicine but also in veterinary medicine for the treatment of similar diseases is valuable, e.g.
bei Pferden, Hunden oder Katzen.in horses, dogs or cats.
Es ist ein Kennzeichen des vorliegenden pharmazeutischen Präparates, daß Magen- und Darmstörungen rasch behoben werden.It is a characteristic of the present pharmaceutical preparation, that stomach and intestinal disorders are quickly remedied.
Die Erfindung wird in den nachfolgenden Beispielen beschrieben, ohne sie jedoch einzuschränken. Die Temperaturen sind in Celsiusgraden angegeben.The invention is described in the following examples without however, limit them. The temperatures are given in degrees Celsius.
Beispiel 1 2-Äthoxy-6 , 9-diaminoacridin-lactat 20 mg 5,7-Dichlor-8-oxy-chinaldin 30 mg αα-Diphenyl-α-(ß-methoxyäthoxy)-essigsäure-(ß-dimethylaminoäthyl) -ester als orotsaures Salz 5 mg basisches Wismutnitrat 50 mg Aluminlumt annat 20 mg Apfelpectin 875 mg 1000 mg Diese Bestandteile werden gut gemischt und zu Tabletten im Gewicht von 1 g gepreßt oder in Kapseln abgefüllt.Example 1 2-Ethoxy-6,9-diaminoacridine lactate 20 mg 5,7-dichloro-8-oxy-quinaldine 30 mg αα-diphenyl-α- (ß-methoxyethoxy) acetic acid (ß-dimethylaminoethyl) -ester as orotic acid salt 5 mg basic bismuth nitrate 50 mg aluminum annate 20 apple pectin 875 mg 1000 mg These ingredients are mixed well and pressed into tablets weighing 1 g or filled into capsules.
Beispiel 2 2-Äthoxy-6,q-diaminoacridin-lactat 30 mg 5 ,7-Dichlor-8-oxy-chinaldin 30 mg αα-Diphenyl-α-(ß-methoxyäthoxy)-essigsäure-(ß-dimethylaminoäthyl)-ester als orotsaures Salz in Schellack eingeschlossen 10 mg Wismutnitrat 50 mg Al. tannicum 20 mg Fel. tauri 30 mg Apfelpectin 230 mg 400 mg werden zu einem Drageekern gepreßt und mit einem Dragee-Überzug folgender Zusammensetzung versehen: Diäthylphthalat 3,0 mg Celluloseacetat-phthalat 10,0 mg Talkum 57,0 mg Stärke (nicht quellend) 2,5 mg Titandioxyd 1,0 mg Gummi arabicum 1,4 mg Gelatine 0,2 mg Zucker 165,0 mg Als Farbe: Orange-gelb in Spuren Indigotin in Spuren Der Kern wird lageweise mit einer wässrigen Suspension der vorliegenden Zusammensetzung solange überzogen, bis er vollständig bedeckt ist. Dann folgt ein Überzug mit einer gefärbten Zuckerlösung. Die rohen Dragees in roter Farbe werden gut getrocknet und in einer Poliertrommel poliert.Example 2 2-Ethoxy-6, q-diaminoacridine lactate 30 mg of 5, 7-dichloro-8-oxy-quinaldine 30 mg αα-diphenyl-α- (ß-methoxyethoxy) acetic acid (ß-dimethylaminoethyl) ester Enclosed as orotsate in shellac 10 mg bismuth nitrate 50 mg Al. tannicum 20 mg Fel. tauri 30 mg apple pectin 230 mg 400 mg are pressed into a tablet core and provided with a dragee coating of the following composition: diethyl phthalate 3.0 mg cellulose acetate phthalate 10.0 mg talc 57.0 mg starch (non-swelling) 2.5 mg titanium dioxide 1.0 mg gum arabic 1.4 mg gelatin 0.2 mg sugar 165.0 mg as Color: Orange-yellow in traces Indigotine in traces The core is layered with a aqueous suspension of the present composition coated until it is completely covered. This is followed by a coating with a colored sugar solution. The raw dragees in red color are well dried and placed in a polishing drum polished.
Beispiel 3 als Pulver 2-thoxy-6,9 ,9-diaminoacridin-lactat 10 mg 5,7-Dichlor-8-oxy-chinaldin 25 mg αα-Diphenyl-α-(ß-methoxyäthoxy)-essigsäureß-dimethylaminoäthyl)-ester als orotsaures Salz in Carnaubawachs eingeschmolzen und gepulvert 10 mg Wismutnitrat (basisch) 50 ag Aluminiumtannat 10 mg Apfelpectin 300 mg Pfefferminzöl 30 mg Die 30 mg Pfefferminzöl werden in Apfelpectin eingesaugt, sodann wird alles gemischt und diese Mischung zusammen mit 4 g Apfelpectin und 1 g Sorbit vermischt und in Tüten abgefüllt.Example 3 as powder 2-thoxy-6,9,9-diaminoacridine-lactate 10 mg 5,7-dichloro-8-oxy-quinaldine 25 mg of αα-diphenyl-α- (ß-methoxyethoxy) -acetic acid, β-dimethylaminoethyl) ester Melted orotsaures salt in carnauba wax and powdered 10 mg bismuth nitrate (basic) 50 ag aluminum tannate 10 mg apple pectin 300 mg peppermint oil 30 mg die 30 mg of peppermint oil are sucked into apple pectin, then everything is mixed and this mixture mixed together with 4 g apple pectin and 1 g sorbitol and in Bottled bags.
Beispiel 4 Granulat Aus der Zusammensetzung des Beispiels 3 wird ein Granulat nach herkömmlicher Arbeitsweise angefertigt und in Tüten gefüllt.Example 4 Granules The composition of Example 3 becomes a Granules made according to the conventional method and filled in bags.
Beispiel 5 I II III IV V VI VII in mg mg mg mg mg mg mg 2-Äthoxy-6,9-diaminoacridin-lactat 30 20 20 - - 10 -5,7-Dichlor-8-oxy-chinaldin 50 50 ~ 60 60 80 80 αα Diphenyl-α-(ßmethoxyäthoxy)-essigsäure-(ß-dimethylaminoäthyl)-ester als orotsaures Salz - 10 20 5 10 - 10 Wisautnitrat (basisch) - - - 100 80 80 80 Aluminiumtannat (al. tannici) - - - - - - -Apfelpectin 420 - 460 833 730 800 -Die Zusammensetzung I - VII wird analog don Beispielen 1 - 4 verarbeitet.Example 5 I II III IV V VI VII in mg mg mg mg mg mg mg of 2-ethoxy-6,9-diaminoacridine lactate 30 20 20 - - 10 -5,7-dichloro-8-oxy-quinaldine 50 50 ~ 60 60 80 80 αα Diphenyl-α- (ßmethoxyethoxy) -acetic acid- (ß-dimethylaminoethyl) -ester as orotsaures Salt - 10 20 5 10 - 10 Wisaut nitrate (basic) - - - 100 80 80 80 Aluminum tannate (al. tannici) - - - - - - -Apple pectin 420 - 460 833 730 800 -The composition I-VII is processed analogously to Examples 1-4.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19691963496 DE1963496A1 (en) | 1969-12-18 | 1969-12-18 | Stomach and intestinal disorders treatment - compsn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19691963496 DE1963496A1 (en) | 1969-12-18 | 1969-12-18 | Stomach and intestinal disorders treatment - compsn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1963496A1 true DE1963496A1 (en) | 1971-06-24 |
Family
ID=5754278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691963496 Pending DE1963496A1 (en) | 1969-12-18 | 1969-12-18 | Stomach and intestinal disorders treatment - compsn |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE1963496A1 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2417982A1 (en) * | 1978-02-24 | 1979-09-21 | Novex Foreign Trade Co Ltd | SOLID PHARMACEUTICAL PRODUCT CONTAINING A BISMUTH SALT, ADMINISTRABLE BY ORAL ROUTE, PRESENTING AN INCREASED ACTIVITY RATE AND A CONSTANT AND PREDETERMINED SOLUBILITY RATE |
| EP0206625A3 (en) * | 1985-06-13 | 1989-04-05 | Barry James Marshall, M.D. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO1989003219A1 (en) * | 1987-10-12 | 1989-04-20 | Borody Thomas J | Improved method for treatment of gastrointestinal disorders |
| AU623868B2 (en) * | 1987-10-12 | 1992-05-28 | Capability Services Pty. Limited | Improved method for treatment of gastrointestinal disorders |
| US5171575A (en) * | 1987-01-19 | 1992-12-15 | Nisshin Flour Milling Co., Ltd. | Process for preventing diarrhea in animals |
| US5601848A (en) * | 1985-06-13 | 1997-02-11 | The Procter & Gamble Company | Methods for the treatment of gastrointestinal disorders |
| US6258376B1 (en) | 1994-05-02 | 2001-07-10 | Josman Laboratories, Inc. | Method of making chewing gum containing colloidal bismuth subcitrate |
| US6372784B1 (en) | 1995-02-07 | 2002-04-16 | Josman Laboratories, Inc. | Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
| US6379651B1 (en) | 1995-02-07 | 2002-04-30 | Josman Laboratories | Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases |
| US6426085B1 (en) | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| US6902738B2 (en) | 1994-05-02 | 2005-06-07 | Josman Laboratories, Inc. | Topical oral dosage forms containing bismuth compounds |
-
1969
- 1969-12-18 DE DE19691963496 patent/DE1963496A1/en active Pending
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2417982A1 (en) * | 1978-02-24 | 1979-09-21 | Novex Foreign Trade Co Ltd | SOLID PHARMACEUTICAL PRODUCT CONTAINING A BISMUTH SALT, ADMINISTRABLE BY ORAL ROUTE, PRESENTING AN INCREASED ACTIVITY RATE AND A CONSTANT AND PREDETERMINED SOLUBILITY RATE |
| EP0206625A3 (en) * | 1985-06-13 | 1989-04-05 | Barry James Marshall, M.D. | Methods and compositions for the treatment of gastrointestinal disorders |
| US5601848A (en) * | 1985-06-13 | 1997-02-11 | The Procter & Gamble Company | Methods for the treatment of gastrointestinal disorders |
| US5171575A (en) * | 1987-01-19 | 1992-12-15 | Nisshin Flour Milling Co., Ltd. | Process for preventing diarrhea in animals |
| WO1989003219A1 (en) * | 1987-10-12 | 1989-04-20 | Borody Thomas J | Improved method for treatment of gastrointestinal disorders |
| AU623868B2 (en) * | 1987-10-12 | 1992-05-28 | Capability Services Pty. Limited | Improved method for treatment of gastrointestinal disorders |
| US6258376B1 (en) | 1994-05-02 | 2001-07-10 | Josman Laboratories, Inc. | Method of making chewing gum containing colloidal bismuth subcitrate |
| US6426085B1 (en) | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| US6616938B2 (en) | 1994-05-02 | 2003-09-09 | Josman Laboratories, Inc. | Method of making chewing gum containing colloidal bismuth subcitrate |
| US6902738B2 (en) | 1994-05-02 | 2005-06-07 | Josman Laboratories, Inc. | Topical oral dosage forms containing bismuth compounds |
| US6372784B1 (en) | 1995-02-07 | 2002-04-16 | Josman Laboratories, Inc. | Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
| US6379651B1 (en) | 1995-02-07 | 2002-04-30 | Josman Laboratories | Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0032562B1 (en) | Dipyridamol retard-forms and process for their preparation | |
| DE69003568T2 (en) | Delayed-release medicines. | |
| DE1467976A1 (en) | Carriers for pharmaceuticals and processes for their manufacture | |
| DE1106454B (en) | Coating agents for drugs | |
| US2887438A (en) | Prolonged action tablets | |
| EP0568577B1 (en) | Orally administerable drugs for the treatment of central dopamine deficiency conditions | |
| DE2813480A1 (en) | MEDICINAL DEPOT PREPARATION OF THE MULTI-UNIT DOSE TYPE | |
| DE1467961A1 (en) | Delayed release medicament carriers and processes for their manufacture | |
| DE3627423A1 (en) | MEDICINAL PRODUCTS CONTAINING DIPYRIDAMOL OR MOPIDAMOL AND O-ACETYLSALICYL ACID OR THEIR PHYSIOLOGICALLY COMPATIBLE SALTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR COMBATING THROMBUS FORMATION | |
| CH658188A5 (en) | STORAGE STABLE QUICK DISASSEMBLING PHARMACEUTICAL PRESSELS. | |
| DE1492208A1 (en) | Tablet manufacturing process | |
| DE2246037B2 (en) | Orally applicable drug with delayed absorption in suspension form | |
| DE2950463A1 (en) | BALINE ACID CONTAINING PHARMACEUTICAL PREPARATION WITH EXTENDED EFFECT | |
| DE1963496A1 (en) | Stomach and intestinal disorders treatment - compsn | |
| DE60006362T2 (en) | CAPSULES WITH COMPOSITIONS CONTAINING LORATADINE AND PSEUDOEPHEDRIN | |
| DE69627880T2 (en) | DILTIAZIC MICROGRANULATES WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES | |
| DE2854651C2 (en) | ||
| JPS6113683B2 (en) | ||
| DE2251250C3 (en) | Process for the production of high-dose antibiotic tablets | |
| DE2259646A1 (en) | HIGH DOSE TABLETS OF CEPHALOSPORIN DERIVATIVES AND THE METHOD FOR THEIR MANUFACTURING | |
| DE2434849C2 (en) | Cardio-strengthening dosage unit with gelatin capsule | |
| DE2035739A1 (en) | Oral enzyme prepsn - consisting of granulate with gastric juices-resistant coating in tablet or capsule form | |
| EP0164571A2 (en) | Sustained-release forms of alpha-(2,5-dimethoxy phenyl)-beta-glycinamidoethanol and process for their preparation | |
| EP0478837B1 (en) | Lactulose preparation and its manufacturing process | |
| DE2404257C3 (en) | Process for the production of pharmaceutical granules with a depot effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |